RIBOZYME AND OMICS
announced on the 16th that it won the most promising pipeline award in the gene
therapy category at the "Asia-Pacific Cell & Gene Therapy Excellence
Awards" (ACGTEA) of the "Cell & Gene Therapy World Asia
2022" (CGTWA 2022) held in Singapore.
is an event to share representative technologies of cell and gene therapy.
the conference which is followed after the award, the "next-generation
cell gene therapy" session was announced.
the presentation, Rznomics explained the current status of candidate substances
(pipelines) including trans-splicing ribozyme based gene therapy platform
technology and liver cancer therapy currently undergoing clinical trials. As
a company with first-in-class platform technology, it presented technological
innovation and vision.
plans to apply for clinical trials for glioblastoma patients in the United
States and Korea in the first quarter of next year. In the second half of next
year, the U.S. is also planning to perform clinical trials on hereditary
Lee, CEO of Rznomics, said, "This award will be a great help to executives
and employees who have a desire to develop new drugs and those who supported
Rznomics," adding, "We will do our best to achieve better